IMPORTANCE: @entity68503 is a vascular endothelial growth factor receptor 2, @entity1916 , and @entity8958 multitargeted @entity4149 kinase inhibitor that has antiangiogenic and antitumorigenic properties with potential efficacy for the treatment of several @entity5 . Cutaneous reactions, one of the most frequently observed adverse effects associated with @entity4149 kinase inhibitors, can significantly affect @entity1 ' quality of life and drug adherence and represent a major therapeutic challenge to maximizing the efficacy of targeted @entity5 therapy. OBJECTIVE: To describe the frequency and spectrum of skin reactions in @entity1 with @entity189 receiving @entity14820 as monotherapy. DESIGN, SETTING, AND @entity1 : A single-institution study at the Clinical Research Center at the National Institutes of Health included 41 consecutive adults with metastatic, progressive @entity189 enrolled in a National @entity5 Institute open-label, nonrandomized, phase 2 clinical trial. @entity1 receiving @entity14820 were evaluated for the development of skin reactions at each treatment visit from October 2012 to June 2014 by the primary oncology team and referred for dermatologic evaluation as appropriate. MAIN OUTCOMES AND MEASURES: A detailed history, full-body physical examination, and clinical photographs of cutaneous lesions were obtained. RESULTS: Of 41 consecutive @entity1 who received @entity14820 , 30 (73%) developed 1 or more cutaneous toxic effects. Adverse events included hand-foot skin reaction (22 [54%]), generalized pigment dilution and/or hair depigmentation (18 [44%]), xerosis (8 [20%]), scrotal erythema/ulceration (6 [15%]), and nail @entity548 (5 [12%]). Eighteen @entity1 (44%) had 2 or more cutaneous adverse events. Reactions developed in 17 of 30 @entity1 (57%) during the first month of @entity14820 treatment and in 24 of 30 (80%) by the second month. Of @entity1 with skin toxic effects, dose reduction was required for symptom management in 9 of 30 @entity1 (30%), and treatment discontinuation was required in 4 of 30 (13%). CONCLUSIONS AND RELEVANCE: @entity14820 monotherapy is associated with 1 or more cutaneous adverse events in most @entity1 . Early detection and prompt treatment may increase @entity1 ' adherence to @entity4149 kinase inhibitor therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01688999.

Cutaneous adverse effects associated with the @entity4149 -kinase inhibitor XXXX .

@entity8958 :: ('5979', 'Gene') :: ['RET'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS'] @entity548 :: ('MESH:D006470', 'Disease') :: ['splinter hemorrhages'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'Cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma'] @entity14820 :: ('MESH:C558660', 'Chemical') :: ['cabozantinib', 'Cabozantinib'] @entity68503 :: ('CHEBI:72319', 'Chemical') :: ['Cabozantinib S-malate'] @entity1916 :: ('4233', 'Gene') :: ['c-MET'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity14820 :: (MESH:C558660,Chemical) :: ['cabozantinib']
